Vaccinex Tech Validated in OmniAb Proof-of-Concept Collaboration

 Application is based on proprietary poxvirus system that enables Hard-to-Drug Complex Proteins to be expressed at high levels in their “native conformation” so as to efficiently induce and select specific antibody-producing cells

Successfully applied in proof-of-concept evaluation by OmniAb to select antibodies against ion channel and chemokine receptor proteins in transgenic animals

https://www.globenewswire.com/news-release/2023/09/28/2751172/34858/en/Vaccinex-s-Next-Generation-ActivMAb-Technology-Published-in-mAbs-a-Leading-Biotech-Journal-and-Validated-in-OmniAb-Proof-of-Concept-Collaboration.html